Filmed in September 2020 – Backed by extensive clinical evidence, the Decipher Prostate Genomic Classifier helps clinicians and their patients with prostate cancer make informed decisions for personalized treatment.
Join Dr. Edouard Trabulsi, FACS, Professor and Vice Chair Department of Urology, and Dr. Robert Den, Associate Professor of Radiation Oncology, Thomas Jefferson University, as they discuss how genomic testing, like Decipher Prostate, can guide and inform multidisciplinary management of post-radical prostatectomy (RP) radiation therapy.
Dr. Trabulsi and Dr. Den cover clinical data that informs decisions about early versus late radiation therapy for men with adverse pathology, along with prospective validation of the Decipher Prostate clinical utility and impact on treatment choices. They discuss how Decipher Prostate improves the ability to identify patients’ risks for metastasis, prostate cancer-specific mortality, and overall survival, and through a series of case studies, they demonstrate the impact of genomic testing on treatment decisions in the post-RP setting.
Key topics
- 0:00 – Introduction
- 1:20 – Decipher Overview
- 3:20 – Clinical Data Background
- 6:00 – Guideline Support for Adjuvant/Early RT
- 10:00 – Reasons for Underutilization
- 13:00 – Importance of Endpoints
- 15:30 – Whole-Transcriptome Analysis
- 34:00 – Utility of Decipher Prostate
- 37:00 – RAVES and RADICALS Data
- 41:00 – pt3a Treatment Strategies
- 41:30 – Case Studies
- 57:00 – Key Points & Takeaways
- 59:00 – Q&A
Speakers
Edouard Trabulsi, M.D.
Thomas Jefferson University
Robert Den, M.D.
Thomas Jefferson University
Tags
On Demand
Decipher Prostate